Rising drug cost impacts on cost‐effectiveness of 2 chemotherapy regimens for intermediate‐risk rhabdomyosarcoma: A report from the Children's Oncology Group-Reference-Cited by-同舟云学术

Rising drug cost impacts on cost‐effectiveness of 2 chemotherapy regimens for intermediate‐risk rhabdomyosarcoma: A report from the Children's Oncology Group

Published:2021-10-08 Issue:2 Volume:128 Page:317-325
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Russell Heidi V.¹²^ORCID,Chi Yueh‐Yun³,Okcu M. Fatih¹,Bernhardt M. Brooke¹,Rodriguez‐Galindo Carlos⁴,Gupta Abha A.⁵^ORCID,Hawkins Douglas S.⁶^ORCID

Affiliation:

1. Texas Children's Cancer Center Baylor College of Medicine Houston Texas

2. Center for Medical Ethics and Health Policy Baylor College of Medicine Houston Texas

3. Department of Pediatrics and Preventative Medicine University of Southern California Los Angeles California

4. St. Jude Children's Research Hospital Memphis Tennessee

5. Hospital for Sick Children Toronto Ontario Canada

6. Seattle Children's HospitalUniversity of WashingtonFred Hutchinson Cancer Research Center Seattle Washington

Funder

National Cancer Institute

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33917

Reference49 articles.

1. Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas

2. Two Consecutive Phase II Window Trials of Irinotecan Alone or in Combination With Vincristine for the Treatment of Metastatic Rhabdomyosarcoma: The Children's Oncology Group

3. Randomized Phase II Window Trial of Two Schedules of Irinotecan With Vincristine in Patients With First Relapse or Progression of Rhabdomyosarcoma: A Report From the Children's Oncology Group

4. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children’s Oncology Group

5. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Children's Oncology Group's 2023 blueprint for research: Pharmacy;Pediatric Blood & Cancer;2023-07-17

2. A multicenter phase II trial of primary prophylactic PEG‐rhG‐CSF in pediatric patients with solid tumors and non‐Hodgkin lymphoma after chemotherapy: An interim analysis;Cancer Medicine;2023-05-15

3. Treatment location, drug prices drive the cost effectiveness of paediatric RMS chemotherapy;PharmacoEconomics & Outcomes News;2021-10